We analyze the prognosis of these two diseases, focusing on single-hit or multi-hit status of TP53 mutation and treatments received. Results Median age at diagnosis was 71 years (range, 44-87 years) with a male predominance (67%). Thirty-five (84%) patients were diagnosed of AML and 7...
•新增了参考文献5:BernardE,TuechlerH,GreenbergPL,etal.MolecularInternationalPrognosisScoringSystemforMyelodysplasticSyndromes.NEJMEvid2022;1:Evidoa2200008. MDS-C(2/3) •MDS中经常发生体细胞突变的基因 修订了第1句:此表列出了与疾病MDS相关的体细胞(获得性,非先天性)的可能基因突变因此是MDS的推定证据。
MDS的诊疗研究进展
Prognosis in MDS-Molecular Committee MDS预后国际工作组分子 委员会数据汇总分析 3392例MDS患者 NGS检测27个基因,1.5% 为阳性标准 12个基因提示生存缩短: ASXL1, CBL, EZH2, IDH2, NF1, NRAS, PTPN11, RUNX1, SRSF2, STAG2, TP53, U2AF1 仅有SF3B1提示生存期延长 Bejar, et ...
Mutationally, secondary AML appears at least as similar to MDS-EB2 as to de novo AML. Patients presenting with de novo AML but with secondary-type AML mutations seem to have the same poor prognosis associated with clinically defined secondary AML. Seattle data indicate that after accounting for...
•新增了参考文献5:BernardE,TuechlerH,GreenbergPL,etal.MolecularInternationalPrognosisScoringSystemforMyelodysplasticSyndromes.NEJMEvid2022;1:Evidoa2200008. MDS-C(2/3) •MDS中经常发生体细胞突变的基因 修订了第1句:此表列出了与疾病MDS相关的体细胞(获得性,非先天性)的可能基因突变因此是MDS的推定证据。